
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions




Our Biopharma Team
Our leading team of professionals leverages their knowledge, experience and singular healthcare focus to help our clients achieve their financing and strategic objectives.

Tom Davidson is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman. He serves on the Firm’s executive committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Tom is focused on building a world class Mergers & Acquisitions business at Leerink Partners.
Over the last decade, Tom has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.
Tom joined the Firm in 2024 from PJT Partners where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.
Tom graduated from Yale University, summa cum laude and Phi Beta Kappa, with a BA in Economics and received his MBA from the Wharton School of the University of Pennsylvania. Tom is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.

Dan Dubin, M.D., is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman and sits on the Firm’s executive committee.
For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.
Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Gabe Cavazos is a Senior Managing Director in Investment Banking at Leerink Partners.
Gabe joined Leerink Partners in 2008 from J.P. Morgan where he was a member of the Mergers & Acquisitions group in the New York office. He covers East Coast and European biopharma companies and has 15+ years of transaction experience, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to J.P. Morgan, he spent eight years in the pharmaceutical industry at Merck and Pfizer.
He earned his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan.

Jon Civitarese is a Senior Managing Director in Investment Banking at Leerink Partners.
Jon was one of the Firm’s earliest employees when he joined in 1995, providing advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financings as part of the Firm’s investment banking team. In addition to his primary banking responsibilities, he has also served as a senior member of the equity capital markets and syndicate team since 2001.
He began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.

Grant Curry is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.
Prior to joining the Firm in 2024, Grant was most recently a Managing Director at Dyalco, specializing in mergers & acquisitions and activism defense. He has advised on a wide range of biopharma and health care transactions, including Bristol-Myers Squibb in its acquisition of Celgene, Bristol-Myers Squibb in its acquisition of MyoKardia, Novartis on its spin-off of Sandoz, Novartis in its acquisition of AveXis, Novartis in the divestment of its consumer healthcare joint venture interest to GSK, Amgen in its acquisition of Otezla, and Charles River Laboratories in its acquisition of Cognate. Prior to joining Dyalco in 2016 as one of its first employees, Grant was a member of the Global Healthcare Group of UBS.
He earned an M.B.A. from The University of Chicago Booth School of Business and a B.A. from Whitman College.

Murphy Gallagher is a Senior Managing Director in Investment Banking at Leerink Partners.
Murphy focuses on the Biopharma sector and has over 17 years advising companies on capital markets, mergers and acquisitions and strategic advisory assignments. He is based in San Francisco and focuses on companies in western North America and the Asia Pacific region. He joined the firm in 2009 and prior to that was at Merrill Lynch, where he was a member of the Global Healthcare Investment Banking Group.
He earned a B.A. from Georgetown University.

Andrew Gitkin is a Senior Managing Director in Investment Banking at Leerink Partners.
Andrew joined the Firm in 2024 from Raymond James & Associates where he most recently served as a Senior Managing Director and Vice Chairman in the healthcare investment banking group. He brings over 25 years of healthcare-focused experience specializing in the biopharma and medical device sectors, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to Raymond James, he served as a Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company, and Senior Vice President at Moelis & Company. Andrew’s previous experience also includes roles as a Vice President of Tavistock Life Sciences and leading a biotechnology start-up. He started his career in the Equity Research Departments of SalomonSmithBarney and UBS.
He is a member of the UCLA Health System Board, and he earned his BBA from Emory University.

Dr. Anurag Jindal is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector. He has over two decades of experience in the biopharma industry, as an investment banker, a consultant, and in strategic roles at a major pharmaceutical company.
Prior to joining Leerink Partners in 2021, Anurag was a Managing Director in the Healthcare Investment Banking group at Bank of America where he focused on strategic advisory and capital markets transactions for public and private companies in the biotech sector. Previously to his work at Bank of America, Anurag was the Deputy Head of Pharma M&A and in the Pharma Strategy Group at Novartis in Switzerland and in the Healthcare Investment Banking group at JP Morgan in both New York and San Francisco. He started his career as a Pharmaceutical Analyst at Health IQ in Los Angeles.
He holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a M.D. from the University of Southern California.

Dan Lepanto is a Senior Managing Director at Leerink Partners and leads the Biopharma Mergers & Acquisitions team.
Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.
He earned his B.S. in Finance with High Honors from Pennsylvania State University.

Sean Pitt is a Senior Managing Director in Investment Banking at Leerink Partners.
Sean has over a decade of healthcare investment banking experience and joined Leerink Partners in 2017. He has advised a broad range of biopharma companies across equity and strategic advisory assignments and transactions, having worked on over 200 transactions during his career.
He earned a B.S. from The University of Sydney, Australia.

Brian Swanson is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector and is based in New York.
Brian joined Leerink Partners in 2014 and has executed more than 100 M&A and capital markets transactions for public and private biopharma companies. Prior to Leerink Partners, he was a management consultant for PwC focused on strategy and operations for companies in the healthcare and technology sectors.
He earned an M.B.A. from Cornell University and a B.S. from Stanford University.

Jason Truman is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.
Prior to joining the Firm in 2024, Jason most recently was Senior Managing Director in the Biopharma Investment Banking Practice of Guggenheim Securities. Jason brings over 20 years of investment banking experience, where he advised a wide variety of domestic and international biopharma clients in connection with mergers and acquisitions, divestitures, spin-offs/split-offs, takeover defense, proxy contests and capital raising. Specifically, Jason has advised on strategic transactions that have involved leaders in the space including such companies as Gilead, Merck, Pfizer, Alexion, Arena Pharmaceuticals, NGM Bio, and Revolution Medicines. Prior to joining Guggenheim Securities, Jason specialized in mergers and acquisitions in the biopharma space working at firms including Credit Suisse and Morgan Stanley.
He earned his MBA from the Darden School of Business at the University of Virginia and a BBA from the Ross School of Business at the University of Michigan.